View Online
January 23, 2020

How Will You Celebrate Heart and Black History Month?

Please let us know if you are speaking, presenting, moderating, hosting and/or participating in a February Heart or Black History Month program - likewise, if you will be appearing on a podcast/radio or TV news show, a Facebook Live, IGTV video or YouTube channel for a special "February Month" interview. ABC would like to share this information with other members.


News From Medscape
The following recommended articles on are freely available through the partnership between ABC and Medscape, no registration or login required.
'Hotspotting' Hospital Care Fails to Cut Readmissions in Randomized Trial
A multidisciplinary clinical and social intervention program aimed at patients deemed to be "superutilizers" of the healthcare system failed to make a difference in 180-day readmission rates in a randomized, controlled trial.
Ten Ways Doctors Lose Patients and Respect on Social Media
Some doctors stay away from social media because they see numerous potential risks. Physicians in particular are vulnerable on social media. They face strict restrictions on patient privacy, the need to present absolutely correct medical information, and pressure to present a public image that is above reproach. However, these concerns don't mean you have to give up on social media. They just mean that you need to understand the specific risks and take measures against them.
First Appropriate-Use Criteria for Imaging in Congenital HD
For the first time, appropriate-use criteria (AUC) have been issued to provide guidance on which cardiac imaging modalities to use — and which to avoid — in the follow-up care of children and adults with established congenital heart disease (CHD).
HRS, Industry Team Up on 'Wearables' Best-Practices Guidance
Clinicians have teamed with industry on a best-practices document for wearable biometric-monitoring devices to help prepare the public for what is looking to be a revolution in its relationships with both technology and healthcare professionals.
Items of Interest
How Seven North Carolina Clinics Increased Patient Use of Statins By 349%
A two-year collaboration between the North Carolina chapter of the American College of Cardiology (NCACC) and North Carolina Association of Free and Charitable Clinics (NCAFCC) was successful in providing thousands of underserved heart patients with free lipid-lowering therapy and clopidogrel. The pilot study, published in the Journal of the American College of Cardiology, launched in 2016 and involved seven free clinics in North Carolina.
On the Front Lines of Health Equity: Six Physicians/Public Health Experts Who Devote Themselves To Make Changes
Physicians see stark disparities in health outcomes for different patient populations all the time. The diversity of causes mirrors the distinct efforts of Minnesota clinicians to tackle the complex roots of these disparities. Many physicians and public health experts aren’t waiting for others to dive in and develop solutions for health equity. These six individuals - including Dr. LaPrincess Brewer - are leading the way, from teaching future physicians about implicit bias to developing community-led health programs and advocating for policy changes.
FIRST OPINION: Why Black Doctors Like Me Are Leaving Faculty Positions in Academic Medical Centers
Dr. Uché Blackstock, Founder and CEO of Advancing Health Equity, writes a “deeply personal” piece about why she left her faculty position in academia and what losing Black faculty means for students and patients of color.
Lp(a) Reduction Contributes to Alirocumab's Treatment Benefit: ODYSSEY Outcomes
Among patients with acute coronary syndromes treated with a PCSK9 inhibitor on top of high-intensity statin therapy, new ODYSSEY Outcomes data suggest that a reduction in lipoprotein(a) contributes to the overall reduction in major adverse cardiovascular events independent of the effect on LDL cholesterol levels. The reduction in LDL cholesterol accounted for a larger proportion of the benefit observed with alirocumab (Praluent; Sanofi/Regeneron), but the PCSK9 inhibitor-induced reduction in Lp(a) still played a role in the benefit seen in the trial, say investigators. Published in the Journal of the American College of Cardiology, the new study is a prespecified analysis of the ODYSSEY Outcomes trial.
CV Safety Trial for Lorcaserin Picks Up Cancer Signal: FDA
The US Food and Drug Administration is alerting physicians and the public that a clinical trial - CAMELLIA-TIMI 61 - designed to assess the cardiovascular safety of the obesity drug lorcaserin (Belviq/Belviq XR; Eisai), which showed no sign of higher CV events in 2018, is now suggesting a possible increased risk of cancer.
Amarin Tailors Educational Campaign to People at Persistent CV Risk
Amarin announced the launch of “True to Your Heart,” a new educational campaign geared toward heart patients who remain at a persistent risk for CVD despite being treated with statins and other standard-of-care therapies. The campaign was born from the results of a survey involving 255 primary care physicians and 243 cardiologists who regularly treat patients with persistent heart disease. The poll revealed that 60% of healthcare professionals (HCPs) believe that less than half of their patients with persistent CVD who are treated with statins realize that they’re still at risk for future cardiovascular events.
Tech Company Develops BP-Monitoring Earbuds
Blood pressure-monitoring technology is hitting the wearables market hard this year, and tech companies are vying to create the optimal tool for tracking BP on the go. But one company thinks they already have it figured out, according to CNET—in the form of BP-monitoring earbuds.
Featured Articles by Members
ABC Members: We welcome your published research submissions and articles for inclusion in future issues of Clinical Updates and Insights. Email Rachel Williams at and please attach file or include links to the original published work and/or abstract.
Multimodality Cardiac Imaging in the Era of Emerging Cancer Therapies
Co-authored by Daniel Addison (with Michael A. Biersmith, Matthew S. Tong, Avirup Guha, and Orlando P. Simonetti)
Approaching this review from the perspective of treatment‐related cardiovascular toxicities, we examine evolving applications of imaging in contemporary cardio‐oncology with specific focus on the more novel and emerging anticancer therapies, examining broad categories of cancer therapeutics, highlighting specific agents that have been implicated in cardiotoxicity, and discussing optimal cardiac imaging modalities for each class. We also consider amyloidosis, in light of recent interest.
The Role of CYP450 Drug Metabolism in Precision Cardio-Oncology
by Olubadewa A. Fatunde and Sherry-Ann Brown
As many novel cancer therapies continue to emerge, the field of Cardio-Oncology (or onco-cardiology) has become crucial to prevent, monitor and treat cancer therapy-related cardiovascular toxicity. Here we review the role of cytochrome P450 (CYP450) enzymes in the field of Cardio-Oncology. We highlight the importance of cardiac medications in preventive Cardio-Oncology for high-risk patients or in the management of cardiotoxicities during or following cancer treatment.
OPINION ARTICLE: Preventive Cardio-Oncology: The Time Has Come
By Sherry-Ann Brown, MD
Dr. Sherry-Ann Brown explores what Preventative Cardio-Oncology is and why the time has come for cardiovascular disease (CVD) prevention to play a more prominent role in cardio-oncology and what steps can be taken to achieve this new paradigm.

We LOVE to LEARN how our ABC Members are making a difference! Please Share. Giving a keynote speech? Presenting at a Grand Round? Receiving an Award? Interviewed by the Press? Published in a journal? Presenter or Panelist at a Conference? Graduating? Email Rachel Williams at or please tag or DM us on Facebook, Twitter or Instagram with links/details, so we can spotlight your excellence in our newsletter!

Event of Interest
Upcoming Diversity Dialogue Webinars - Save the Date

The Institute for Diversity and Health Equity (IFDHE) in collaboration with the AHA is pleased to feature the Carolyn Boone Lewis Equity of Care honorees. Equitable care ensures that all patients receive the highest quality of care, care that is individualized to the needs of every person that needs it and the community being served by a hospital or health system. The Equity of Care Award honors noteworthy leaders who have demonstrated a high level of success in reducing health care disparities and the promotion of diversity and inclusion within their organization.

January 28, 2020, 12:00pm CT, featuring honoree Northwell Health, Great Neck, NY
Dr. Jennifer Mieres
Senior Vice President, Center for Equity of Care Chief Diversity and Inclusion Officer
Northwell Health
Michael Wright
Vice President of Diversity and Health Equity Northwell Health System



ABC's Dr. Jay Brown Best Abstract Competition

Submit your abstract summarizing any problem that relates to cardiovascular disease whether it is: Clinical, Basic or Population Science. Abstract must be original scientific research and must not have been published previously.

Any physician/scientist presently in a residency or cardiology fellowship training program and active in the Association of Black Cardiologists is eligible. Not an ABC member? Click here to join or renew.

Four (4) outstanding abstracts will be selected for presentation at ABC's Annual Fellows Program on Friday, March 27, 2020 at the Hilton Chicago in Chicago, IL.

The winner of the Dr. Jay Brown Best Abstract Competition will also receive a $1,000 cash award.

Deadline to submit your abstract is February 7, 2020.


Associate Editor George A. Mensah, MD, director of the Center for Translation Research and Implementation Science at the National Heart, Lung, and Blood Institute, National Institutes of Health (NIH) and William T. Riley, PhD, director of the Office of Behavioral and Social Sciences Research, NIH, invite manuscript submissions for a special issue of Ethnicity & Disease to be published in November 2020.

Please submit a structured abstract of up to 400 words by Monday, Feb 10, 2020.


NIMHD Accepting Proposals for Research on Biopsychosocial Factors of Social Connectedness and Isolation

NIMHD is supporting two new funding opportunities, PAR-19-373 (R01 Clinical Trials Not Allowed) and PAR-19-384 (R01 Basic Experimental Studies with Humans Required), to understand the interrelation between social connectedness and social isolation on health disparity populations and health disparities (how the mechanisms, processes, and trajectories of social relationships affect outcomes in health, illness, and more.). This work includes the impact of interpersonal and systemic discrimination and microaggressions on social connectedness and isolation. This research aims to identify unique challenges and intervention targets for health disparity populations. NIMHD encourages investigators to participate in this important public health activity and welcomes inquiries concerning these FOAs. Review the funding opportunities for more information on eligibility and application submissions.

Application Due Date: March 17, 2020.


Upcoming Events

This email was sent to ##email## by Association of Black Cardiologists, powered by Powered by Multiview's Content Marketing
Archive | View Online | Unsubscribe | Subscribe